Aljabry M
J Hematop. 2024; 16(1):27-31.
PMID: 38175368
DOI: 10.1007/s12308-022-00528-1.
Sircar A, Singh S, Xu-Monette Z, Coyle K, Hilton L, Chavdoula E
Leukemia. 2023; 37(10):2094-2106.
PMID: 37598282
PMC: 10539170.
DOI: 10.1038/s41375-023-02006-8.
Hernandez-Boluda J, Pereira A, Zinger N, Gras L, Martino R, Nikolousis E
Bone Marrow Transplant. 2022; 57(3):416-422.
PMID: 35066569
DOI: 10.1038/s41409-021-01553-x.
Cowell J, Hu T
Cancer Drug Resist. 2021; 4:607-619.
PMID: 34734169
PMC: 8562765.
DOI: 10.20517/cdr.2021.30.
Buchwalow I, Atiakshin D, Samoilova V, Boecker W, Tiemann M
Histochem Cell Biol. 2017; 149(2):169-177.
PMID: 29197996
DOI: 10.1007/s00418-017-1624-y.
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I
Cancer Res. 2016; 76(22):6471-6482.
PMID: 27671675
PMC: 5290120.
DOI: 10.1158/0008-5472.CAN-15-3569.
Mediastinal Mass with Hyper-eosinophilia in a Young Boy -A Diagnostic Dilemma.
Parambil A, Prem S, Jacob P, Nair R
J Clin Diagn Res. 2016; 10(7):XD03-XD04.
PMID: 27630938
PMC: 5020259.
DOI: 10.7860/JCDR/2016/19615.8202.
Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.
Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Martinez J
Blood. 2014; 123(10):1516-24.
PMID: 24408322
PMC: 3945862.
DOI: 10.1182/blood-2013-07-518381.
Fine-needle aspiration cytology of T-lymphoblastic lymphoma associated FGFR1 rearrangement myeloproliferative neoplasm.
Patel R, Sheehan A, Finch C, Lopez-Terrada D, Hernandez V, Curry C
Diagn Cytopathol. 2013; 42(1):45-8.
PMID: 23904402
PMC: 4100463.
DOI: 10.1002/dc.23030.
Dysregulated signaling pathways in the development of CNTRL-FGFR1-induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models.
Ren M, Qin H, Kitamura E, Cowell J
Blood. 2013; 122(6):1007-16.
PMID: 23777766
PMC: 3739028.
DOI: 10.1182/blood-2013-03-489823.
Clonal Hypereosinophilia with ETV6 Rearrangement Evolving to T-Cell Lymphoblastic Lymphoma: A Case Report and Review of the Literature.
Moita F, Bogalho I, Alaiz H, Parreira J, Frade M, Nunes A
Case Rep Hematol. 2013; 2013:652745.
PMID: 23710385
PMC: 3654631.
DOI: 10.1155/2013/652745.
Acute Lymphoblastic Leukemia with Eosinophilia and Strongyloides stercoralis Hyperinfection.
Nesheli H, Moghaddam T, Zahedpasha Y, Norouzi A
Iran J Pediatr. 2012; 21(4):549-52.
PMID: 23056848
PMC: 3446142.
Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.
Ren M, Qin H, Ren R, Cowell J
Leukemia. 2012; 27(1):32-40.
PMID: 22781593
PMC: 3629706.
DOI: 10.1038/leu.2012.188.
Cardiac disease in a case of precursor B acute lymphoblastic leukaemia with eosinophilia(ALL/Eo).
Asadi Gharabaghi M, Aghajanzadeh P, Zahedi G, Borji R, Derakhskan L, Sattarzadeh R
BMJ Case Rep. 2012; 2012.
PMID: 22665861
PMC: 3263020.
DOI: 10.1136/bcr.04.2011.4128.
BCR-ABL-negative chronic myeloid leukemia.
Burgstaller S, Reiter A, Cross N
Curr Hematol Malig Rep. 2010; 2(2):75-82.
PMID: 20425354
DOI: 10.1007/s11899-007-0011-5.
Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase.
Ren M, Li X, Cowell J
Blood. 2009; 114(8):1576-84.
PMID: 19506298
PMC: 2731638.
DOI: 10.1182/blood-2009-03-212704.
The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report.
Goradia A, Bayerl M, Cornfield D
Int J Clin Exp Pathol. 2008; 1(5):448-56.
PMID: 18787627
PMC: 2480578.
14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells.
Dong S, Kang S, Gu T, Kardar S, Fu H, Lonial S
Blood. 2007; 110(1):360-9.
PMID: 17389761
PMC: 1896121.
DOI: 10.1182/blood-2006-12-065615.
Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease.
Kasyapa C, Kunapuli P, Hawthorn L, Cowell J
Blood. 2006; 107(9):3693-9.
PMID: 16410451
PMC: 1895775.
DOI: 10.1182/blood-2005-04-1505.
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.
Chen J, DeAngelo D, Kutok J, Williams I, Lee B, Wadleigh M
Proc Natl Acad Sci U S A. 2004; 101(40):14479-84.
PMID: 15448205
PMC: 521956.
DOI: 10.1073/pnas.0404438101.